The involvement of dysregulated c-myc expression has been well established in certain virus-or chemical-induced and naturally developing tumors (1-5). Most of murine plasmacytomas and human Burkitt's lymphomas have been shown to carry a chromosomal translocation involving c-myc and Ig genes (2-5). In such tumor cells, only the c-myc transcripts from the translocated allele are constitutively expressed, while the normal allele is completely suppressed, suggesting that the translocation affects the expression of the c-myc gene of the normal allele as well as that of the translocated one (6, 7). Recently it has been shown that Ig heavy chain enhancer (Ew) t-driven c-myc can induce immature B cell tumors in the transgenic mice (8), which is a direct demonstration of the involvement of the translocated c-myc gene in B lymphomagenesis . Moreover, tumors developed in such transgenic mice have been demonstrated to be monoclonal or oligoclonal, suggesting that the malignant transformation requires secondary events following an abnormal expression of c-myc gene. It is likely that such events might be determined or influenced by factors intrinsic to certain cells, or by environmental and genetic factors. Thus, the transgenic mice carrying activated oncogenes such as c-myc can also be a useful system to study such factors influencing tumorigenesis.
The involvement of dysregulated c-myc expression has been well established in certain virus-or chemical-induced and naturally developing tumors (1) (2) (3) (4) (5) . Most of murine plasmacytomas and human Burkitt's lymphomas have been shown to carry a chromosomal translocation involving c-myc and Ig genes (2) (3) (4) (5) . In such tumor cells, only the c-myc transcripts from the translocated allele are constitutively expressed, while the normal allele is completely suppressed, suggesting that the translocation affects the expression of the c-myc gene of the normal allele as well as that of the translocated one (6, 7) . Recently it has been shown that Ig heavy chain enhancer (Ew) t-driven c-myc can induce immature B cell tumors in the transgenic mice (8) , which is a direct demonstration of the involvement of the translocated c-myc gene in B lymphomagenesis . Moreover, tumors developed in such transgenic mice have been demonstrated to be monoclonal or oligoclonal, suggesting that the malignant transformation requires secondary events following an abnormal expression of c-myc gene. It is likely that such events might be determined or influenced by factors intrinsic to certain cells, or by environmental and genetic factors. Thus, the transgenic mice carrying activated oncogenes such as c-myc can also be a useful system to study such factors influencing tumorigenesis.
To study the genetic or environmental factors that affect the myc-induced lymphomagenesis, we introduced the translocated human c-myc gene into two inbred strains ofmice, C57BL/6 and C3H/HeJ, which have different genetic backgrounds. We have observed the preferential development ofT lymphomas in C3H/HeJ transgenic mice, whereas B6 transgenic mice mostly developed B lymphomas. Furthermore, the bone marrow transfer experiments using prelymphomatous transgenic mice suggest that environmental factors might influence the development ofT lymphoma in C3H/HeJ mouse.
Materials and Methods
Production ofTansgenic Mice. The Ep-myc used is an 11.5-kb Eco RI fragment from a cosmid DNA clone, cU23, derived from the non-Hodgkin's lymphoma Manca, which consists of a translocated human c-myc gene fused head to head with the Cu gene ( Fig. 1) (9) . Transgenic mice were produced by microinjecting -200 copies of the gene into the fertilized eggs of C57BL/6 or C3H/HeJ mice as described (10) . The offsprings were screened for the integration of the transgene by Southern blot analysis of DNA from tail tips using the Eco RI/Cla I fragment of human c-myc gene as a probe.
Flow Cytometry Analysis. Flow cytometry analysis was performed using aFACS 440 equipped with dual lasers. The mAbs used were FITC-conjugated anti-IgM (rat IgG), FITC-anti-B220 (6112, rat IgG), FITC-anti-Lyt-2 (53-6, rat IgG), FITC-antiThy-1 .2 (30H12, rat IgG), FITC-anti-I-A b (25-9-17 , mouse IgG2), biotinylated (bi)-anti-IgD (anti-5a or 5b), bi-anti-B220, bi-anti-L3T4 (GK1.5, rat IgG), bi-anti-Ly-1 (53-7, rat IgG), bi-anti-I-Ek (13/4, mouse IgG2a), and phycocyanin (PC)-labeled anti-CD3 (2011, hamster IgG). Single cell suspensions were obtained from bone marrow, lymph node, spleen, and thymus in deficient RPMI medium containing 3% FCS and 0.1% NaN3. Washed cells were incubated with several combinations ofvarious antibodies for 20 min at 4°C. After washing, Texas red avidin was added as a second step to develop biotinylated antibodies. Propidium iodide was included for the last 5 min ofa second step to stain dead cells. The stained cells were examined by multiparameter FACS and the list mode data were collected into a VAX11/730 computer and analyzed by a DESK program developed at Stanford University, Stanford, CA.
Southern BlotAnalysis. High molecular weight DNA was prepared with 250 Wg ofproteinase K (Sigma Chemical Co., St. Louis, MO) in 2 ml of 1 x SSCA mM EDTA/0 .Io7o NaDodS04 at 37°C for 3-12 h. After digestion, phenol, phenol/chloroform (1 :1, wt/vol), and chloroform extractions were performed and DNA was precipitated with ethanol. 5 Rg of the DNA was digested with Xba I for analysis of the Ig heavy chain locus and with Hind III for analysis of the K chain locus and TCR a chain locus. Digested DNA was separated on 0.5°70 agarose gel, and transferred to Gene Screen Plus'"' Hybridization Transfer Membrane (NEN Research Products, Boston, MA) in a solution of 0.4 N NaOH/0 .6 M NaCl. Blots were hybridized with 32 P-labeled DNA probes at 65'C in a buffer of 1 M NaCI/0 .05 M Tris-HCl, pH 7 .5/200 Rg/ml salmon sperm DNA. Blots were washed in 2 x SSC at room temperature for 10 min, in 2 x SSC/logo SDS at 65'C for 60 min, in 0.1 x SSC at room temperature for 60 min, and processed by autoradiography. The DNA probes used in this study were a 3.8-kb Xba I fragment of the mouse germline Jx region (11), a 1.7-kb Pst I/Eco RI fragment ofJK (12), a 1.7-kb Pst I fragment of DO, region (13) , and a 2.4-kb Hind III/Eco RI fragment of D/32 region (13) . S1 Nuclease Protection Assay. Total RNA was prepared from lymphoma cells and prelymphomatous splenic cells and thymocytes by the guanidium isothiocyanate/CsC12 method (14) . SSDNA probe for S1 analysis was prepared as follows: an Xba I/Pst I fragment ofcU23 (9) or an Sst I/Pvu II fragment of PKO-myc (6, 15, 16) was cloned into M13mp18 vector and single-stranded 32 P-labeled DNA was synthesized by the primer extension method (17) . After digestion with Xba I or Sst I, the ssDNA probe was separated by PAGE. For Sl protection assay, 25 Rg of total RNA was co-precipitated with the specific DNA probes (100,000 cpm), heated at 95'C for 10 min, and incubated for 14 h at 601C in 80% formamide/40 mM Pipes/0.4 M NaCl/ 1 mM EDTA. Hybridized materials were treated with 250 U of Sl nuclease (17) for 40 min at 30'C in 280 mM NaCl/50 mM NaoAc (pH 4.6)/4.5 mM ZASo4/20 p.g/ml salmon sperm DNA. After PAGE under denaturing conditions, Sl-resistant species were visualized by autoradiography.
Bone Marrow or Fetal Liver Transplantation. 101 bone marrow cells treated with antiThy-1 .2 (IgM mAb, DAIICHI Kagaku) plus complement (LOWTOX-M Rabbit Complement, Cedar Lane Laboratories, Hornby, Ontario) and 5 x 106 of fetal liver cells from prelymphomatous Ep.-myc mice were transferred into lethally irradiated normal B6 (878 rad) or normal C3H/HeJ mice (950 rad). At the same time, 106 cells from bone marrow or fetal liver of the same Ett-myc mice were inoculated intravenously into unirradiated syngeneic mice. Transgenic mice, whose cells did not induce tumors in unirradiated recipients, were recognized as prelymphomatous ones. Structure of EIt-myctransgene. As the transgene, an 11 .5-kb Eco RI fragment containing tJ the Cp-c-myc joining region (arrow : recombination site) was prepared from a cosmid DNA clone(cU23) of the Manca cell line that has the chromosomal translocation(t(8 :14)(g24 ;g32)) involving the Clc-c-myc joining region . Exons are shown by solid boxes. EA(E) is a transcriptional enhancer element of the human heavy chain locus (9) . Restriction sites: RI, EcoRI ; X, Xbal; P, Pstl . oligoclonal . One pre-B cell lymphoma developed in mouse 119 and a B cell lymphoma in mouse 229 had also the rearrangement of TCR /3 chain gene . One mouse (225), developed a CD4+ , CD8 + , Thy-1.2' lymphoma . These results indicate that Ej,-myc B6 transgenic mice mostly develop B cell tumors although these mice also have a potential to develop T cell tumors at low frequencies. Seven C3H/HeJ transgenic mice carrying EI,-myc gene were produced . Around 5 wk of age, all developed lymphomas that involved mainly the mesenteric lymph nodes and the spleen but rarely the thymus . In contrast to B6 transgenic mice, six of seven C3H/HeJ transgenic mice developed lymphomas that express T cell phenotypes. B cell lymphoma arose only in one C3H/HeJ transgenic mouse (454). The surface phenotypes of the tumors developed in these mice are summarized in Table  II and representative FAGS analyses are shown in Fig. 3 . The differentiation stages of T lymphomas were variable in each C3H/HeJ transgenic mice . For instance, lymphomas that developed in mouse 480 expressed both CD4 and CD8. Mice 241 and 450 developed CD4+/CD8 -and CD4 -/CD8 + tumors, respectively. Some lym- 
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Developments ofBand
T LYMPHOMAGENESIS IN Ey-myc TRANSGENIC MICE dency of B and T lymphoma development might be due to preferential activation of B-or T-lineage cells in B6 or C3H/HeJ transgenic mice, respectively. To test this possibility, we analyzed the size and surface phenotypes of bone marrow cells, spleen cells, and thymocytes from the prelymphomatous transgenic mice that had not developed tumors. As shown in Fig . 4 , B220+ cells from bone marrow and spleen of both B6 and C3H/HeJ transgenic mice were found to be larger in size and strongly expressed class II antigens compared with those of normal mice, indicating that Blineage cells were similarly activated in prelymphomatous transgenic mice of both strains . However, cell size and numbers of each T cell subsets in thymus derived from both B6 and C3H/HeJ transgenic mice were normal, as shown in Fig . 5 . These results suggest that high frequency of T lymphoma development in C3H/HeJ transgenic mice may not be simply due to the preferential activation of T lymphocytes . The second possible explanation for a high incidence of T lymphoma in C3H/HeJ mice is that the EA.-myc gene might be expressed in Tlineage cells ofC3H/HeJ mice but not of B6 mice. To determine whether there is any difference of Ej.-myc mRNA expression among B and T lymphomas as well as prelymphomatous T and B cells from B6 and C3H/HeJ transgenic mice, RNAs were prepared from these cells and the expression of the transgene was analyzed. As shown in Fig . 6 , four protected bands were observed in B and T lymphomas derived from B6 and C3H/HeJ transgenic mice, respectively, when the fragment of human genomic c-myc DNA was used The human specific c-myc probe was hybridized with total RNAs prepared from M12 (mouse B cell line), 169T (C3H/Hej EIA-myc T lymphoma), 93B (B6 E' U-myc B lymphoma), B6 prelymphomatous EIA-myc spleen, 86 prelymphomatous EA-myc thymus, C3H/Hej prelymphomatons EIA-myc spleen, C3H/Hej prelymphomatous EA-W thymus, B6 normal spleen, and B6 normal thymus . The reported cryptic promoters in intron I of human c-myc were indicated (* and **) and represented by protected bands of -774 and -760 nucleotides. Bands of -660 and -618 nucleotides also represent the probes specifically protectedby human c-myc gene transcripts. (Right) The mouse-specific c-myc probe was used for 51 nuclease analysis. Mouse endogenous c-myctranscripts were detected at 188 nucleotides. In addition to mice shown in this figure, one B6 and two C3H/Hej transgenic mice were examined and also found to express almost equal amounts of human c-myc mRNA in the spleen and the thymus . FAGS analysis showed that B220' B cells in the thymus from a B6 transgenic, acontrol 86, a C3H/Hej transgenic, and a control C3H/Hej mouse were 1.7, 1.1, 1.3, and 1.0%, respectively, indicating that EA-myc mRNA in of transgenic mice is not due to contaminating B cells.
as a probe. The two larger bands of -774 and 460 nucleotides represent the mRNA transcribed from cryptic promoters in intron I of the human c-myc gene as previously reported (9) . Smaller but intense bands of -660 and -618 nucleotides were consistently observed in lymphomas from transgenic mice but not in control cells, indicating that these bands also represented the transcripts of human c-myc gene. These four bands were also observed in splenocytes and thymocytes from prelymphomatous B6 and C3H/HeJ transgenic mice but not in those of control mice. Expression levels ofEli-myc mRNA were found to be almost comparable among splenocytes and thymocytes in both strains. Endogenous murine c-myc expression was completely inhibited in B and T lymphomas ofboth strains. The expression ofmurine c-myc mRNA was lower in prelymphomatous B and T cells of transgenic mice than in those of normal mice. These results demonstrated that the Ep-rnyc gene is equally expressed in prelymphomatous B and T cells from B6 and C3H/HeJ transgenic mice, and that the expression of endogenous c-myc gene was suppressed in cells expressing Ep,-myc mRNA.
Transfer of Bone Marrow or Fetal Liver Cellsfrom Prelymphomatous Tansgenic Mice into Normal Mice. No differences of Ep.-myc expression and lymphocyte activation were observed between B6 and C3H/HeJ transgenic mice. These results suggested the possibility that environmental factor(s) may enhance the development or the growth of B and T lymphomas in B6 and C3H/HeJ transgenic mice, respectively. However, it was impossible to carry out the crossing experiment ofthe transgenic mice to study this possibility, since such mice died from tumors before giving rise to progeny. Therefore, bone marrow or fetal liver transfer experiments were done by using primary transgenic mice. Bone marrow or fetal liver cells of prelymphomatous B6 or C3H/HeJ transgenic mice were transferred into lethally irradiated normal B6 and C3H/HeJ mice, and the recipient mice were monitored for the development of tumors for 1 yr. 10 of 11 B6 and 7 of 9 C3H/HeJ recipients developed lymphomas between 65 and 95 d after transplantation. As shown in Table III Bone marrow or fetal liver cells from a single donor were transfered into one or several recipients ; bone marrow of 91 to one B6, fetal liver of 3-22 to one B6, fetal liver of 3-24-2 to two B6 and two C3H/HeJ, fetal liver of 3-24-5 to two B6 and two C3H/HeJ, bone marrow of 3-25 to two B6 and two C3H/HeJ, and bone marrow of 4-30 to three B6 and three C3H/HeJ recipients . Number of recipient mice . . Bone marrow cells from this mouse were transferred into two B6 and two C3H/HeJ recipients . B lymphomas developed in one B6 and one C3H/HeJ recipient and T lymphomas developed in the others . As shown in Fig. 7 , all lymphomas that developed in different recipients showed the Eu,-myc integration and the distinct rearrangement pattern ofIg heavy chain and TCR /3 chain genes, indicating that these tumors are derived from the same donor bone marrow, but different clonal origins. All these results suggest that T lymphomas Tumors of distinct clonal origins were developed in respective recipients that were transferred with bone marrow cells from a single Ep-myc transgenic mouse. 10 7 bone marrow cells from the B6 transgenic mouse were transferred into two B6 and two C3H/HeJ recipient mice. DNA were prepared from tumors developed in each recipient mouse and analyzed preferentially develop or grow in the environment of C3H/HeJ mice, and that irradiated mice might provide the similar environment that supports the development of T cell tumors .
Number of recipient mice that developed B (B) or T lymphomas (T) or no lymphoma ( -
Discussion
In this study, we have produced transgenic mice carrying the Ep-myc gene by microinjecting the transgene into B6 or C3H/HeJ fertilized eggs and have shown that both B and T cell lymphomas can arise in these mice. Most lymphomas that developed in B6 transgenic mice were of B cell type as expected from the construction of the transgene in that human c-myc gene was under the control of Ig enhancer element. In contrast to B6 transgenic mice, C3H/HeJ transgenic mice preferentially developed T cell tumors . Several studies on productions of transgenic mice carrying Epmyc have been reported (8, 18, 19) . Such transgenic mice have been shown to develop mostly pre-B cell tumors . These findings are in striking contrast to our results. However, they have injected the transgene into (B6 x SJL)F2 or (B6 x CDI)Fl, both of which retain partially B6 background. Moreover, the SJL strain has been shown to develop frequently spontaneous reticulum cell sarcomas that are of pre-B cell origins (20) . Thus, our results raised the possibilities that the strain dependency of B or T lymphoma development might exist. Therefore, it is interesting to know what determines the development of B or T lymphoma in our B6 or C3H/HeJ transgenic mice, respectively.
The phenotypic analysis of lymphocytes from B6 and C3H/HeJ transgenic mice at a prelymphomatous stage showed increases in cell size and MHC class II expression of B cells from such mice of both strains, which is in good agreement with the finding by Langdon et al . (21) . However, the expression of Ep-myc transgene did neither perturb the development of T cells in thymus or increase the size of T cells in the transgenic mice of both strains. The S1 nuclease analysis of splenocytes and thymocytes demonstrated that almost equal amounts of human c-myc mRNA were expressed in spleens and thymuses of both strains of transgenic mice, indicating that there is no difference in the transgene expression in B and T cells of B6 and C3H/HeJ transgenic mice. These results suggest that a high incidence of B or T lymphomas in B6 or C3H/HeJ transgenic mice could not be simply explained by the differential activation of or the differential Ep-myc expression in B or T lineage cells.
In contrast to our transgenic mice, the Eli-myc transgenic mice produced by others (8, 18, 21, 22) have been shown to express the transgene specifically in B lineage cells. The reason for this discrepancy is not clear at the moment . However, it has been reported that the transgenic mice introduced with productively rearranged p chain gene express the transgene in certain population of T as well as B cells (23) . Furthermore, several pieces of evidence have also been reported that Ig enhancer element can be active in T as well as B cells (24) (25) (26) (27) . Thus it is reasonable to assume that the expression of human c-myc gene is also under the influence of the adjacent Ig enhancer even in T cells. We used the human Ep-myc gene cloned from a nonHodgkin lymphoma, Manca, in which human Ig enhancer has been translocated into intron 1 of the c-myc gene (9) . Other studies used the Ep-myc construct, in which the mouse or the human c-myc gene is under the control of the murine Ig enhancer (8, 18, 19) . One of the three was the naturally translocated Ep-myc and the others were the artificially constructed ones. Therefore, it is possible that the extent of Eu-myc gene expression in T cells may reflect particular constructs . It should be noted that the EA-myc construct used in this study lacks exon 1. The exon 1 is known to be lost in the translocated c-myc gene of some of human Burkitt's lymphoma cells and murine plasmacytoma cells (5) . v-myc also lacks the equivalent sequence (28) (29) (30) . Some investigators have proposed that the exon 1 sequence plays an important role in the negative control of c-myc gene transcription (31) (32) (33) . Others have suggested that the untranslated sequence of c-myc mRNA derived from exon 1 may be involved in the translational control (34, 35) . Furthermore, it has been also reported that c-myc mRNA lacking exon 1 sequence is more stable than the complete c-myc mRNA (36) (37) (38) . It is thus possible that our transgene might be more active than the myc construct used by others, which contained exon 1 (8, 18) or heterologous SV40 promoter (19) . Alternatively, the EI.-myc transcripts of the transgenic mice produced here might be more stable .
There are two possible explanations for a high incidence of T lymphoma in the C3H/HeJ transgenic mice; (a) the frequency of transformation of B and T cells might be intrinsically determined, or (b) the development or growth of T lymphoma in C3H/HeJ mice might be accelerated by certain environmental factors such as growth factors or endogenous viruses. One piece of evidence supporting the former possibility is that the C3H/HeJ strain has a functional defect in B cells and is a low responder to LPS (39, 40) . Therefore, this defect might be involved in less frequent B lymphoma development in transgenic mice of this strain . However, we could not observe any difference in EA.-myc-induced distortion of B lymphocyte activation in prelymphomatous transgenic mice of both strains, as discussed above, suggesting that the defect of C3H/HeJ did not affect Eu-myc-induced B cell activation .
The microenvironment of each strain is also an important factor that influences the growth or development of lymphomas. When the bone marrow or fetal liver cells from the prelymphomatous B6 or C3H/HeJ transgenic mice were transferred to lethally irradiated C3H/HeJ mice, the developed lymphomas were mostly of T cell type . Half of the tumors developed in irradiated B6 mice, which received hemopoietic stem cells from B6 and C3H/HeJ transgenic mice, were also of T cell type . Although the number of experiments was small because of the limited availability of transgenic mice, these results indicate the presence of the necessary conditions in C3H/HeJ to support the growth or the development of T lymphomas, respectively. Furthermore, irradiation might modify the environment of B6 mice, resulting in increased development of T cell lymphomas.
One of the environmental factors affecting lymphoma development in the transgenic mice might be an endogenous retrovirus . Recently, Klinken et al . (41) demonstrated that v-rafcould convert the phenotype of B lymphomas developed in EI.-myc transgenic mice to that of macrophages. This suggests that retrovirus infection could have an influence on the lineage determination of tumors . However, the high incidence of T lymphomas in C3H/HeJ transgenic mice cannot be explained simply by the phenotype conversion of tumors from B to T lineage since some of T cell lymphomas developed in C3H/Hej transgenic mice conserved the germline configuration of Ig heavy chain genes.
Kaplan et al . (42) (43) (44) (45) have shown the high incidence of T cell lymphomas of graft origins in the irradiated mice that receive unirradiated thymus graft and have isolated radiation leukemia virus (RadLV) as the agent that induces tumors of graft origin by indirect mechanisms in irradiated recipients . The recent study by Lie-berman et al . (46) has confirmed the indirect mechanism of radiation-induced lymphomagenesis but has demonstrated that such lymphomagenesis is mediated by the transmissible agent that is not identical to RadLV. Recently it has also been reported that irradiation of hematopoietic stroma cells induces the production of certain growth factor(s) that support the development of myelogenous leukemia (47) . Supposing such an agent or a growth factor exists even at considerably low levels in normal C3H/HeJ, it might positively affect the development or growth of T lymphoma in the prelymphomatous transgenic mice of C3H/HeJ. Irradiation of B6 mice may induce such an agent or growth factor and provide the environment to support the T lymphoma development. However, the identification of viral agents or factors, which influence the development of T and B cell tumors, will require further studies.
In contrast to Ep-myc transgenic mice produced by others (8, 18, 19, 48) , our C3H/HeJ transgenic mice developed mostly T lymphomas, which represent various differentiation stages of T cells. Although a number of transgenic mice carrying various activated oncogenes have been reported, the incidence of T lymphoma is considerably low (see reference 49 for review). Recently it has been reported that murine leukemia virus (MuLV) infection accelerated the development of T lymphoma in Ep.-pim-1 transgenic mice, although uninfected transgenic mice developed T lymphomas at a low frequency (5-10%) and after a relatively long latent period (3-7 mo) (50) . Similarly to T lymphomas in our C3H/HeJ transgenic mice, tumors developed in E/A-pim-1 represented different T cell subpopulations, CD4+/CD8 + tumors and CD4+/CD8 -tumors . Therefore, those transgenic mice and ours and tumors developed in such mice will be very useful for the study of T cell differentiation pathways, as well as for the elucidation of the mechanism of T lymphomagenesis .
Summary
The transgenic mice were produced by injecting eggs of B6 and C3H/HeJ mice with the human Ep-myc gene . Preferential development of B lymphomas was observed in the B6 transgenic mice, whereas the C3H/HeJ transgenic mice developed mostly T lymphomas. The phenotypic activation of B lineage cells but not of T lineage cells was detected in the prelymphomatous transgenic mice of both strains. The transgene was similarly expressed in B and T cells of the transgenic mice of both strains. These results suggest that a high incidence of T lymphomas in the C3H/HeJ transgenic mice may not be due to the preferential activation of or the preferential Ep-myc expression in T lymphocytes. When the bone marrow or fetal liver cells from the prelymphomatous transgenic mice of both strains were transferred into irradiated normal C3H/HeJ mice, most of the recipients developed T lymphomas. Moreover, even when irradiated B6 mice received the hematopoietic stem cells from the prelymphomatous B6 transgenic mice, the incidence of T lymphoma increased up to 50% . These findings suggest that B6 and C3H/HeJ mice might provide the environment that supports the development or growth of B and T lymphomas, respectively, and that such an environment could be modified by irradiation of the mice.
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